Compare Equinor ASA (EQNR) vs Novavax Inc (NVAX) Price & Performance

Equinor (EQNR) trades at $40.865, down 0.3% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing strong revenue growth of 40% year-over-year. Valuation ratios remain attractive with a P/E of 11.09 and EV/EBITDA of 2.3. Recent news highlights a 22.2% monthly rally, driven by higher energy prices and output, alongside ongoing share buybacks and consistent dividend payments.

The outlook is cautiously positive, supported by robust cash flow and strategic investments in production growth. However, risks include volatile energy prices, execution challenges in portfolio adjustments, and a high tax burden impacting net margins. Analyst sentiment is mixed, with 30% buy ratings but majority holds, reflecting valuation concerns after recent gains.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.